DLA Piper advises Custom Health in its business combination with Berenson Acquisition Corp

DLA Piper advised Custom Health Inc, a digital healthcare firm, in its business combination with Berenson Acquisition Corp. I (BACA), a special purpose acquisition corporation. The business combination is expected to result in Custom Health becoming a publicly listed company.

Custom Health provides a comprehensive technology-enabled medication management and managed care solution, resulting in 98% medication adherence for its patients across the US and Canada. The company is focused on serving poly-med patients with chronic conditions, representing an estimated market of 68 million in the US.

The DLA Piper team that advised Custom Health was co-led by senior counsel Mitchell Marder (Washington, DC) and Jeffrey Selman (San Francisco) and included partners John Maselli (San Francisco), Sarah Kahn, David Kopans and Era Anagnosti (all in Washington, DC), Drew Young (New York), Michele Lara (San Diego), Ben Gipson (Los Angeles), Christina Houston (Wilmington), Russel Drew (Toronto), and Chris Mikson (Philadelphia); of counsel Mimi Brouillette (New York); and associates Melissa Lucar (Los Angeles), and Dan Rosenberg and Kristen Pappas (both in Washington, DC).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 14 consecutive years, according to Mergermarket, and ranked as a top five most active VC legal advisor in the US and number one in VC, PE and M&A in combined global deal volume according to PitchBook.